Chaired by Mohamad Mohty, and featuring Rakesh Popat, Suzanne Lentzsch and Saad Usmani, this CME-accredited symposium focussed on an overview of the multifaceted landscape of BCMA-targeting strategies in multiple myeloma, including anti-BCMA bispecific antibodies, anti-BCMA ADCs, and anti-BCMA CAR-T cells, offering insights into the latest clinical data and their implications for clinical practice. The session concluded with a comprehensive discussion addressing challenges and future needs in myeloma therapy.

Independent symposium organized by Springer Healthcare IME. This program is made possible thanks to an educational grant received from GlaxoSmithKline.